Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.50
Bid: 7.00
Ask: 8.00
Change: 0.00 (0.00%)
Spread: 1.00 (14.286%)
Open: 7.50
High: 7.50
Low: 7.50
Prev. Close: 7.50
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in Pharm2Farm Limited

8 Jul 2019 07:00

RNS Number : 7146E
Braveheart Investment Group plc
08 July 2019
 

8 July 2019

 

Braveheart Investment Group plc

("Braveheart" or the "Group")

 

Investment in Pharm2Farm Limited

 

Braveheart (AIM: BRH), the fund management and strategic investor group, is pleased to announce that it has acquired a 33 per cent. holding in Pharm2Farm Limited ("P2F"). P2F is a spin out from Nottingham Trent University ("NTU") and is based in Nottingham, UK.

 

NTU and P2F have developed and patented a process to increase the bioavailability of trace minerals in plant feeds. Their patented process uses nanotechnology to dramatically improve trace element take-up in both flower and crop farming. P2F produce and sell these products through an exclusive licence to this technology from NTU.

 

Since records began in the 1940's, the nutritional value of the UK's and worldwide crops has diminished dramatically. Many of the intensively grown foods produced can no longer be regarded to be 'as healthy' because they lack the levels of trace elements once present. P2F produces these specialist nutrients in a unique way so that plants can absorb them more effectively.

 

This pioneering technology was initially developed to enrich the nutritional value of potatoes, in conjunction with the Agriculture and Horticulture Development Board ("AHDB") which represents farmers. Preliminary results not only showed a 20 per cent. increase in iron uptake by the tubers, but also an increase in yield and an approximate two-week reduction in the time to harvest. This patented technology has now been developed for use in the growing of other commercial crops, both in soil and hydroponically.

 

The worldwide hydroponics market alone is estimated to be $8.1 billion in 2019 and is expected to continue to grow at a compound annual growth rate of over 12 per cent. to $16.0 billion by 2025, with the EU remaining the largest market for hydroponically produced crops.

The Board of Braveheart believes there is a substantial market opportunity for this technology and is in negotiations to take the Group's shareholding in P2F to 54 per cent. by way of a working capital investment.

 

 

For further information:

 

Braveheart Investment Group plcTrevor Brown, Chief Executive Officer

 

 

Tel: 01738 587555

Allenby Capital Limited (Nominated Adviser and Joint Broker) David Worlidge / Nicholas Chambers

 

Tel: 020 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker) Heena Karani / Lucy Williams

 

Tel: 020 7469 0936

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQCKODKCBKDPOK
Date   Source Headline
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.